Conduct disorder

Recommendations

Info

Kata Martinova sostojba da odrùva konstantna redukcija na labilniot pul na èlezoto koj [to e toksi~na forma na èlezoto. Preliminarnite rezultati pokaùvaat redukcija na preoptovaruvaweto so èlezo vo srceto izmereno preku T2 MRI posle 12 meseci od zapo~nuvawe na tretmanot. (11). Naj~esti sporedni efekti od DFS se lesni do umereni gastrointestinalni tegobi (kako [to se gadewe, povra]awe, abdominalna bolka, dijarea) i koèn ra[. Ovie tegobi obi~no spontano is~eznuvaat. Umeren i neprogresiven porast na serumskiot kreatinin e opserviran kaj okolu 1/3 od pacientite.(12). Hepatalnata funkcija treba da se sledi edna[ mese~no, a pregledi na vidot i sluhot se prepora~uvaat edna[ godi[no. (tab.br.1) Karakteristiki Deferoxamine Deferiprone Deferasirox Doza, mg/kg/d 25-60 75 20-30 Na~in na primena s.c., i.v. 8-12h, per os per os 5 dena/ned 3 h dnevno 1 h dnevno Poluìvot 20-30 min. 3-4 ~. 12-16 ~. Ekskrecija urina, feces urina feces (83%), urina (8%) Tabela. br. 1 Helatori na èlezo Kombinirana helatorna terapija Dostapnosta na tri razli~ni helatori ovozmoùva pravewe na nekolku protokoli za helacija kako [to se monoterapija, alternativna terapija i kombinirana terapija.Izborot na poveke od eden helator ovomoùva fleksibilen pristap za helacija, zna~itelno podobra komplijansa so tretmanot i na toj na~in podobren kvalitet na ìvot. Ponatamu, helatori so razli~ni hemiski karakteristiki moàt da imaat pristap do razli~ni pulovi so èlezo i do razli~ni organi. Alternativnata terapija e ~esta vo klini~kata praktika so voveduvawe na DFP i reducirawe na DFO infuzii, prakti~en priod za podobruvawe na komplijansata kaj pacientite koi ne ja podnesuvaat DFO monoterapija. Prospektivna randomizirana kontrolirana studija koja [to go komparira DFO (dva dena nedelno) i DFP (5 dena nedelno) nasproti standardnata DFO monoterapija (5-7 dena/nedelno) poka- à sli~na efikasnost i ne pogolema razlika vo sporednite efekti. Pri kombiniranata terapija dvata helatori se zemaat vo ist den vo nazna~en broj na denovi. Ovoj protokol se primenuva kaj pacienti koi ne se soglasuvaat so standardnite DFO infuzii ili onie koi pokaùvaat neadekvaten odgovor na poedine~en helator. Kombiniranata terapija so DFO i so DFP efikasno se koristi kako intenzivna helatorna terapija vo tretmanot na seriozna kardijalna sideroza i kardijalna insuficiencija i pokaùva Страна 164
Novini vo pedijatrijata / Godi[na revija 2009 prifatliva tolerabilnost. Zasega DFS ne se kombinira so drugi helatori, poradi toa [to efikasniot i bezbeden profil na vakvite kombinacii ne e sé u[te potvrden. (13). Zaklu~oci Razvojot na novi metodi za procena na koli~inata na èlezo vo organizmot, dostapnosta na pove]e helatori i mo`nosta za planirawe na razli~ni protokoli za helacija im davaat novi mo`nosti na klini~arite za tretman na pacientite so preoptovarenost so èlezo. Site ova bi trebalo da dovede do namaluvawe na morbiditetot i prodolùvawe na preìvuvaweto kaj pacientite so transfuziono i netransfuziono preoptovaruvawe so èlezo. Literatura: 1. Zurlo MG,Stefano P, Borgna-Pignatti, et al. Survival and causes of death in thalassemia major. Lancet 1989;2(8653):27-30 2. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematologica 1996;95:26-36 3. Porter J. Pathophysiology of iron overload. Hematology/Oncology Clinics; Suppl 1, Elsevier Saunders 4. Porter JB, Davis BA. Monitoring chelation therapy to achive optimal outcome in the treatment of thalassemia. Best Pract Res Clin Haematol 2002;15(2):329-68. 5. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000; 343(5):327-31 6. Fischer R, Longo F, Nielsen P et al. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with betathalassemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol 2003; 121:938-948 7. Jensen PD, Jensen FT, Chriistensen T et al. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferroxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 2003;101:4631-4639 8. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89(3):739-61. 9. Brittenham GM, Griffith PM,Nienhuis AW, McLaren CE, et al.Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331(9):567-73. Страна 165
Page 1 and 2:
NOVINI VO PEDIJATRIJATA GODI{NA REV
Page 3:
Od glavniot redaktor Po~ituvani kol
Page 6 and 7:
Mladenović M, Radlović N, Lekovi
Page 8 and 9:
Milena C. Lo Giudice Although all t
Page 10 and 11:
Milena C. Lo Giudice patient will h
Page 12 and 13:
Milena C. Lo Giudice have on the ch
Page 14 and 15:
Страна 14
Page 16 and 17:
Nedeqko Radlovi] nje. Budući da su
Page 18 and 19:
Nedeqko Radlovi] (maksimalno 15 mg
Page 20 and 21:
Gjeorgjina Kuli-Lito Introduction K
Page 22 and 23:
Gjeoorgjina Kuli-Liito The fever ty
Page 24 and 25:
Gjeorgjina Kuli-Lito stenoses in ch
Page 26 and 27:
Страна 26
Page 28 and 29:
@eqko Ron~evi] Will stethoscope sur
Page 30 and 31:
@eqko Ron~evi] Electronic stethosco
Page 32 and 33:
@eqko Ron~evi] 8. Mangione S, Duffy
Page 34 and 35:
Nada Pop-Jordanova a critical role
Page 36 and 37:
Nada Pop-Jordanova response (long-t
Page 38 and 39:
Nada Pop-Jordanova In the following
Page 40 and 41:
Nada Pop-Jordanova From Fig. 4 it i
Page 42 and 43:
Nada Pop-Jordanova References: [1]
Page 44 and 45:
Nada Pop-Jordanova [22] Friesen GM,
Page 46 and 47:
Mirjana Ko~ova Ha[imoto tiroiditis
Page 48 and 49:
Mirjana Ko~ova Slika 2. Devoj~e na
Page 50 and 51:
Mirjana Ko~ova c) Ultrazvu~niot pre
Page 52 and 53:
Mirjana Ko~ova smetaat deka kaj ovi
Page 54 and 55:
Mirjana Ko~ova 10. Pituitary pseudo
Page 56 and 57:
Страна 56
Page 58 and 59:
Qup~o Nikolovski Summary: Regardles
Page 60 and 61:
Qup~o Nikolovski Sugeriran antibiot
Page 62 and 63:
Qup~o Nikolovski - Toj moè da se k
Page 64 and 65:
Qup~o Nikolovski Sugeriran reìm Pr
Page 66 and 67:
Qup~o Nikolovski decata so akcent n
Page 68 and 69:
Qup~o Nikolovski Antibiotici i dija
Page 70 and 71:
Страна 70
Page 72 and 73:
Sowa Peova Abstrakt Efikasno rano o
Page 74 and 75:
Sowa Peova Ranoto klini~ko prepozna
Page 76 and 77:
Sowa Peova - In vitro analiza na in
Page 78 and 79:
Sowa Peova metodi pred da se pojava
Page 80 and 81:
Sowa Peova Страна 80
Page 82 and 83:
Страна 82
Page 84 and 85:
Dafina Kuzmanovska bubre`na insufic
Page 86 and 87:
Dafina Kuzmanovska 1. Abnormalen ra
Page 88 and 89:
Dafina Kuzmanovska Isto taka, nema
Page 90 and 91:
Dafina Kuzmanovska 11. Feather AS,
Page 92 and 93:
Aco Kostovski na holestaza ne se pr
Page 94 and 95:
Aco Kostovski dukcijata na SREBP -
Page 96 and 97:
Aco Kostovski niraat sintezata na l
Page 98 and 99:
Aco Kostovski lema neselektirana st
Page 100 and 101:
Aco Kostovski 2. Tip 1 ili 2 diabet
Page 102 and 103:
Aco Kostovski parcijalna lipodistro
Page 104 and 105:
Aco Kostovski patis od drugi mo`ni
Page 106 and 107:
Aco Kostovski Lipoproteini so mala
Page 108 and 109:
Aco Kostovski kontrola na obeznosta
Page 110 and 111:
Aco Kostovski za razlika od general
Page 112 and 113:
Aco Kostovski NEALKOHOLNA MASTNA BO
Page 114 and 115: Lekovi] Z. SY GILBERT IN CHILDREN:
Page 116 and 117: Страна 116
Page 118 and 119: Aspazija Sofijanova ABSTRAKT Mnogu
Page 120 and 121: Aspazija Sofijanova en~iwa. Zatoa d
Page 122 and 123: Aspazija Sofijanova Odgovor na Krat
Page 124 and 125: Aspazija Sofijanova cira so seriozn
Page 126 and 127: Aspazija Sofijanova sporo. Hepati~n
Page 128 and 129: Aspazija Sofijanova asociran so pos
Page 130 and 131: Aspazija Sofijanova 16. Meyer PG, O
Page 132 and 133: Aspazija Sofijanova 48. Goldman HB.
Page 136 and 137: Du[ko Fidanovski Abstract With intr
Page 138 and 139: Du[ko Fidanovski dilna teìna od 50
Page 140 and 141: Du[ko Fidanovski koncentracii pomal
Page 142 and 143: Du[ko Fidanovski Lekuvawe so surfak
Page 144 and 145: Du[ko Fidanovski EMRT i golem rizik
Page 146 and 147: Du[ko Fidanovski 17. Kotecha S, Wil
Page 148 and 149: Du[ko Fidanovski 46. Corbet A, Long
Page 152 and 153: Filip Duma fluid. Precise diagnose
Page 154 and 155: Filip Duma rata i mozo~noto tkivo,
Page 156 and 157: Filip Duma Diskusija i rezultati: K
Page 158 and 159: Kata Martinova endokrinite `lezdi i
Page 160 and 161: Kata Martinova Evaluacija i monitor
Page 162 and 163: Kata Martinova SQUID (superconducti
Page 166 and 167: Kata Martinova 10. Grady RW., Berdo
Page 168 and 169: Vladimir âdikovski The computer th
Page 170 and 171: Vladimir âdikovski 5. Should peopl
Page 172 and 173: Nadica Ristoska Bojkovska Istorijat
Page 174 and 175: Nadica Ristoska Bojkovska � Virus
Page 176 and 177: Nadica Ristoska Bojkovska na CMV in
Page 178 and 179: Nadica Ristoska Bojkovska Takrolimu
Page 180 and 181: Nadica Ristoska Bojkovska Literatur
Page 182 and 183: Velibor Tasi] Hipourikemija e labor
Page 184 and 185: Velibor Tasi] Ovoj lek go zgolemuva
Page 186 and 187: Velibor Tasi] diabetes mellitus, ma
Page 190 and 191: Emilija Vla[ki diagnostic investiga
Page 192 and 193: Emilija Vla[ki pnevmociti so difuzn
Page 194 and 195: Emilija Vla[ki dijagnosti~koto zna~
Page 196 and 197: Emilija Vla[ki na~eni promeni treba
Page 198 and 199: Katarina Stavri] na prisustvoto na
Page 200 and 201: Katarina Stavri] fagite i eozinofil
Page 202 and 203: Katarina Stavri] telite i decata do
Page 206 and 207: Katerina Obo~ki What is the Practal
Page 208 and 209: Katerina Obo~ki Tret fakt: izloèno
Page 210 and 211: Katerina Obo~ki - izbegnuvawe na ek
Page 212: Katerina Obo~ki Zaklu~ok: Sekoga[ t
show all

Conduct disorder

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?